CLUST-ER HEALTH
SALUTE E BENESSERE

INVESTMENT OPPORTUNITIES

Pharma, biotech, medical devices, digital health & wellness

INVEST IN ITALY

ITA
ITALIAN TRADE AGENCY

INVEST IN ITALY

ITA ITALIAN TRADE AGENCY

CLUST-ER HEALTH SALUTE E BENESSERE

Investment opportunities promoted by Clust-ER Health

Innovation projects by companies & universities

Pharma & Supplements

IVD & Medical Devices

Digital Health & Wellness

Inhalable Teicoplanin by Neupharma

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a particular challenge in cystic fibrosis (CF). The prevalence of MRSA in individuals with CF has increased dramatically over the last 15–20 years. Individuals with persistent MRSA infection have decreased life expectancy compared to those who remain MRSA negative.

Field of activity and technology

The repositioning by nebulization of an established glycopeptide antibiotic (teicoplanin, very effective against MRSA) could solve the problem of the chronic infection. This approach may become the standard therapy for the treatment of lung infection in CF patients, avoiding the risks connected to systemic administration and reducing the risk of resistance development.

Development stage

Phase 1 successfully completed



Inhalable Teicoplanin by Neupharma

BUSINESS PROPOSAL

Cystic fibrosis is a rare disease, and MRSA lung infection affects approximaely 25% of CF patients, therefore it is a rare condition within a rare disease.
Due to the very high medical need and the rarity of the condition, a simplified development path can be agreed with FDA: there is the possibility to complete the clinical development plan involving a limited number of patients in the trials.
Based on these assumptions, considering that the strategy is a repositioning development, time and costs can be significantly reduced compared to a usual development path. Moreover, the formulation of inhalable teicoplanin, with its customized nebulizer, has been granted an Orphan Drug Designation by both EMA and FDA and an Orphan Pediatric Designation by FDA.

U.S. FOOD & DRUG ADMINISTRATION

Office of Orphan Products Development
Food and Drug Administration
WO32- 5295
10903 New Hampshire Avenue
Silver Spring, MD 20993

MAY 2 4 2018

Pursuant to section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), your orphan-drug designation request of teicoplanin is granted for *treatment of Staphylococcus aureus lung infections in cystic fibrosis.* Please be advised that it is the

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/COMP summary report
On an application for orphan medicinal product designation

13 July 2017
EMA/COMP/332077/2017 **CONFIDENTIAL**
Committee for Orphan Medicinal Products

Teicoplanin
Treatment of cystic fibrosis
EMA/OD/085/17
Sponsor: Neupharma S.r.l.

Requested	15 Mln €
Investment target	Pharmaceutical companies interested in rare diseases. Venture Capitalists

HOLOCLAR® tissue engineering by HOLOSTEM

Limbal stem cell deficiency (LSCD) is a rare disease characterized by partial or total loss of limbal stem cells (LSCs) resulting in a progressive loss of vision and blindness affecting one or both eyes
–Ocular burns account for c.19,600 LSCD patients globally
Current treatment paradigm includes supportive management, corneal scraping and cell transplantation
Treatment type and its success varies greatly depending on the cause and severity of the disease
Traditional therapies fail to yield long-term solutions, which only cell grafts have been shown to offer



Field of activity and technology

Holoclar is indicated for the reconstruction of the corneal surface in patients with moderate to severe limbal stem cell deficiency unilateral or bilateral due to ocular burns with a min of 1-2 mm2 of undamaged limbus
Holoclar is the only service platform that offers a comprehensive strategy to manage patients with LSCD, from surgery, to training to post-op advice and following

Development stage

Conditional EU market approval in 2015 as the first stem-cell based therapy approved; US Orphan Drug Designation from the FDA in 2018
Phase 3 successfully completed

HOLOCLAR® tissue engineering by HOLOSTEM

BUSINESS PROPOSAL

Due to the very high medical need and the rarity of the condition, a simplified development path can be agreed with FDA: there is the possibility to complete the clinical development plan in USA, similarly to EU, involving a limited additional number of patients in the trials.

Based on these assumptions, considering that the development was completed in EU and Conditional Marketing Authorization was obtained,, time and costs can be significantly reduced compared to a usual development path. Moreover, the formulation of HOLOCLAR® Advanced Therapy Medicinal Product of Tissue Engineering, with its personalized medicine approach, has been granted an Orphan Drug Designation by both EMA and FDA



Requested	50 Mln €
Investment target	Pharmaceutical companies interested in rare diseases. Venture Capital.

Celector by Stem Sel

Selection of a specific cell type is a fundamental step to obtaining homogenous cell products for ATMP, and Regulatory Agencies ask for new non-invasive techniques to obtain high-quality target cell populations.

Field of activity and technology

Celector® is the only instrument in the world that tag-less analyses and separates living cells exploiting solely their physical characteristics - highlighting even minimal differences: no antibody labeling, as it is necessary with current reference techniques.
Dual features: label-free cell sorting technology and quality control in ATMP production.
Technology and device worldwide are patented. Cells are not manipulated, sterility is kept, and cells can be amplified in a bioreactor for cell production after collection. Celector plays also as a QC system to check the purity and homogeneity of cell products.

Development stage

Market-ready at positioning.
Next Steps: MKT growth and GMP compliance.

Celector by Stem Sel

BUSINESS PROPOSAL

With Celector®, the cell suspension is separated and collected based exclusively on cellular physical parameters such as size, morphology, density and membrane rigidity. Cells that are not identified by a single marker, or are derived from complex biological samples, can be identified and sorted.
As an example, mesenchymal stem cells can be isolated from fresh bone marrow and immediately used for further purposes without additional manipulation or the senescent cells are depleted from the expanded cell culture of adipose stem cells to obtain the most vital and proliferative cells. QC of cell populations used for therapeutic applications is also fundamental, as it is for any other drug. Instruments and methods on the market can't cover all aspects of cell selection and QC and gold standard technologies manipulate cells by using labelled antibodies. Therefore, the innovative approach to QC, selection of the desired cells, and the absence of any manipulation are the EXCLUSIVE ADVANTAGES of Celector® compared to the technologies present on the market.



Requested	2 Mln €
Investment target	Growth

Cor.Con International

CLUST-ER HEALTH SALUTE E BENESSERE

Food supplements from Cor.Con

COGITON: food supplement for Central Nervous System (CNS)
Use: delaying cognitive decline, protecting CNS from oxidative stress and aging in adults, patient affected by early cognitive decline, subjects using drugs such as Donepezil, mental tiredness.
Publications: 3

Development stage *Clinically tested, Innovative Primary Packaging, Short- and Long-Term Treatment.*

TEMPLAR: food supplement for oral contraceptives comorbidities
Use: reducing oxidative stress in women undergoing oral contraceptive treatment.
Publications: 3

Development stage *Clinically Tested, Patent (JP), Innovative Packaging, Unique Market Position*

AFRAGIL: food supplement for women in menopause
Use: to reduce 10+ menopause symptoms and oxidative stress linked to hormone imbalance in women in menopause.
Pubblications: 1

Development stage *Clinically Tested, Large Target Population, Multiple-symptoms treatment*

Cor.Con International

CLUST-ER HEALTH SALUTE E BENESSERE

Functional Food - Noodles by Cor.Con

BUSINESS PROPOSAL

Cor.Con applies a production process able to deliver the full quality the products deserve and searches for pharmaceutical companies or distributors to bring the products into the market.

Functional foods are particular foods representing regular components of the diet, and characterized by the presence of an ingredient or a pool of ingredients that affect specific functions of our body.
Cor.con developed a functional food (noodles) with beneficial effects on metabolic syndrome. The product is ready to be marketed. We are looking for partners that can bring the product into the market and we are also open to collaborations that can support us in expanding scientific evidences and clinical studies for this product.

RATIONAL DESIGN

CLINICAL STUDIES

PATENT & PUBBLICATIONS

READY TO MARKET

Requested	Not specified
Investment target	Pharmaceutical Company, Distributors

HyperTorque by Xenturion

Xenturion Diagnostics srl is a SME dedicated to develop molecular Point Of Care Testing (POCT) diagnostic systems for the detection of pathogens and Anti Microbial Resistance with a One-Health Perspective

Field of activity and technology

In vitro diagnostics
Xenturion diagnostic POCTs are based on a:

- isothermal proprietary technology Hyperfluux® for the simoultaneosly detection of multiple targets (i.e. pathogen + Internal Control in the same reaction) combined with
- easy and quick solution for biological sample preparation Xample-Prep

Xenturion diagnostics POCTs are associated to a miniaturizated device that compact all the instrumentations and equipments needed to run a test; main feature is an Innovative Biosensor affordable in terms of costs effort and with a high sensitivity

Development stage

Hyperfluux technology and Xample prep are mature technologies currently in use in CE-IVD diagnostics kits thus already on the market (TRL9).
Miniaturized device with special and innovative biosensor is a TRL 4/5

Capital raised: *200.000 €*

HyperTorque by Xenturion

BUSINESS PROPOSAL

Point of care Testings (POCT) is a part of the «Decentralized Diagnostics» that can be performed bedside to the patient thus directly «on field» permitting prompt diagnosis and consequent timely treatments.

HyperTorque is a project to miniaturize and compact all the instrumentations and equipments needed to perform Xenturion POCT in a single portable device; main features of HyperTorque is that is based on Hyperfluux ® technology for target amplification combined with innovative bio-sensors for detection.

HyperTorque is designed to significantly reduce the economic impact due to miniaturization and for the fact to be “all in one”; thanks to GPS integration remote monitoring and assistance are possible as well as a prompt communications of positive results to public authorithy.



Requested	1 Mln €
Investment target	Healthcare VC, Growth/Strategic Corporate Investor, In Vitro Diagnostic Corporation

Tech-OECT by Unibo

In pandemic or endemicoutbreak, fast infection tracking, animal reservoir detection and rapid, high-throghput vaccine development are mandatory. However, currentin-vitro assays rely on methods/technologies which (i) need the constant presence (and exposure) of a specialized operator, thusbeingsubjected to human error and interpretation, (ii) onlyprovide quantitative analysis with slow data extraction and end-point test, (iii) lackversatility and efficiency towardsall cell lines and viruses/bacteria/cytophatic effects, and (iv) are cumbersome and expensive, notportable from-and-to different labs.

Field of activity and technology

This electronic, smart, sensorized multi-well can perform an electrical, fast, real-time, and automatized evaluations of cell health status during in-vitro assays, returning quantitative and reliable data. Its use spans from serum-neutralization and vaccine efficacy/lifetime, to anti-viral and anti-bacterical testing, up to toxicological analysis of substances/molecules.
Boosting, wide-spreading and automatizing in-vitro assays would strenghten sanitary industry in vaccine and therapy development, pandemic and infection tracking, and animal reservoir identification reducing personnel cost and exposure, together with in-vivo studies.

Development stage

TRL 6: prototype is currently monitoring up to sixdifferent cell cultures and could be interfaced with an electronic data acquisition setup.



Tech-OECT by Unibo

BUSINESS PROPOSAL

The TECH-OECT boostsin-vitro assays, returning quantitative and real-time information electricallyread by the sensing platform, reducing the operator exposure to potentially dangerous substances and complementingtheir end-point assays. The TECH-OECT overcomes slow data extractions and subjective reading limitationsthatstillaffect some assay evaluations, whilemimicking the standard multiwell template and allowing for the parallel implementation of the gold-standard protocolsconsolidated in the biomedical field.
The electronic platform would be given on loan for use to the scientists/operatorswhile the sensing units (re-usableafter cleaning and sterilization up to threetimes) would be sold as consumables, building user loyalty.



Requested	1 Mln €
Investment target	Prototype scale-up and in-field validation

Implantable device for local release of drugs for spinal cord injury by Unibo

Traumatic spinal cord injury is a catastrophic event that is sudden and unexpected and can be devastating and costly in human and social terms. No therapies are available to interfere with the secondary degeneration, even as "disease-modifying", or to improve the clinical outcome.

Field of activity and technology

The proposed device will target neuroinflammation and related molecular events leading to neurodegeneration using combinations of two drugs loaded in tailored biomaterials. By targeting different events of the cascade at the right time frame, we are able to suppress neuroinflammation and prevent secondary neurodegeneration more efficiently.

Development stage

- *Fully characterized biomaterial and in vitro drug release (Pharmaceutics, 2021, 13:848-867);*
- *PoC study in rat SCI contusion model (J. Neurotrauma, 2020, 37:1708);*
- *Two GLP in vitro studies for safety.*
- *PCT/IT2018/000084*





Implantable device for local release of drugs for spinal cord injury by Unibo

BUSINESS PROPOSAL

What is it? An implantable medicine based on PLLA electrospun scaffold for the local, spinal delivery of a drug combination intended to stop secondary degeneration (Ibuprofen® + T3®).
Exploitable to traumatic brain injury and stroke

What are its unique benefits? Local release of the appropriate concentration of the drug combination, over the appropriate time-window (14 days), avoiding systemic side effects. It Is proposed as “disease-modifying” for an EMA and FDA orphan condition (ORPHA:90058)

Requested	1.4 Mln €
Investment target	Healthcare investors, medical device companies active in the field of regenerative medicine, pharmaceutical companies

Angiopulse by Angiodroid

Angiodroid proposes to develop and commercialize an innovative console to help patients with heart failure and cardiovascular pathologies. In contrast to other intra-aortic balloon pump (IABP) consoles, it is based on passive counterpulsation, attending the patients both in the IABP therapy and the weaning from it.

Field of activity and technology

The console will be used in ICU wards for the resuscitation of patients with cardiac failures and for a gradual assistance towards autonomous cardiac function.

Development stage

TRL 7: a first device was handcrafted for functional verification and bench tests. Once all tests were completed, a first prototype was developed for clinical tests in relevant environment on 10 patients in Sant'Orsola University Hospital. Angiopulse needs a clinical validation according to the newest European standards for medical devices in order to reach TRL9.

Capital raised*: 2 Mln €*

Angiopulse by Angiodroid

BUSINESS PROPOSAL

The Angiopulse project proposes to expand the tractable user base compared to those for whom the typical therapy presents some limitations, such as ventricular arrhythmia problems and patients who need a gradual assistance towards cardiac autonomy, without burdening the heart further. Thanks to its compatibility with any other IABP consoles, Angiopulse's technology allows principal end-users (medical staff) to promptly switch from active (typical) to passive (innovative) counterpulsation, without risking the patients' health.
Considering the environment where an IABP console must be used (Intensive Care Unit, Heart-Surgery), an aspect not to be overlooked when talking about Angiopulse is that it is silent, free of noises that can alert patients that are already shaken.



Requested	15 Mln €
Investment target	Research & Development Funds and Private Stakeholders in the Healthcare field

MyDial by IBD

IBD is an innovative SME, a manufacturer of biomedical devices that has developed MyDial, a new portable device for hemodialysis suitable for home treatment of end stage renal disease patients.

Field of activity and technology

Health science technology- Innovative medical device for hemodialysis. MyDial technology is based on: 1) an original hydraulic circuit (patented) that integrates innovative sensors and actuators; 2) a safety sensor for the venous needle dislodgement monitoring; 3) a telemedicine system for remote monitoring of the patient; 4) a simple and low-cost disposable.

Development stage

TRL 6. Next steps: Product finalization, CE certification according to MDR 2017/745, clinical validation, industrialization and production.

Capital raised

1.5 Mln € (partners and public funds)
1 Mln € VC fund
5 Mln € Grant+equity EIC accelerator (ongoing)



MyDial by IBD

BUSINESS PROPOSAL

Hemodialysis is the most widely used treatment for End Stage Kidney Failure, a deadly condition if left untreated. In-center dialysis is very expensive: in Europe, the annual cost of in-centre hemodialysis treatment is €21 billion, about €60,000/year per patient, which is equivalent to 2% of the healthcare budget, while in the US its annual cost is $42 billion, about $89,000/year per patient.
MyDial is a portable device designed for home hemodialysis that replicates the hospital therapy. It works with an innovative hydraulic circuit and a customized and low-cost disposable, designed to significantly reduce the economic impact of chronic dialysis treatment (up to 70% cheaper than competitors) and make de-hospitalization possible. Thanks to the telemedicine system and the venous needle dislodgement sensor, MyDial allows treatments to be carried out in maximum safety in a domestic environment.
IBD is EN ISO 13485 and EN ISO 9001 certified, MyDial is CE Certified according MDD93/42 with a proprietary technology. Patent PCT

Requested	20 Mln €
Investment target	Growth/Strategic Corporate Investor

Neutronbrush® x nIORT® by TheranostiCentre

Neutronbrush® x nIORT® is a Compact Neutron Generator (CNG) for the treatment of advanced solid tumors developed by TheranostiCentre Srl.

Field of activity and technology

Invention patented by TC Srl which generates a mix of radiation ionizer formed from neutrons “slow down” (le golden bullets silenced) and from gamma radiation (the transversal wave to the bundle of bullets).

Development stage

First laboratory prototype ready and installed at the ENEA Research Centre at Brasimone (BO), Italy. Second prototype in construction for in-vitro and in-vivo tests. Ready in a couple of months.

Capital raised

500.000 €



Neutronbrush® x nIORT® by TheranostiCentre

BUSINESS PROPOSAL

The CNG is a mobile, light, self-shielded, cylindrical-shaped device (about 35cm long x 18 in diameter and with a weight of around 120kg). It is capable of generating a flux of high energy neutrons which can penetrate around 2cm of tumor tissue after surgical resection and with a radiobiological efficiency 16 times higher than the IORT devices currently in use. By breaking the DNA of cancer cells into several parts, it makes it difficult to repair them and therefore reduces the risk of tumor recurrence. The irradiation of CNG acts like a "foam" in the surgical cavity and because it has a uniform distribution inside it, it has no pointing problems, thus allowing to sterilize the walls and margins from the tumor micro-cells present - an action that traditional IORT devices do not allow. The IORT treatment times with the current systems are approximately 30 minutes, while the nIORT® reduces the treatment time by a quarter. The production costs of CNG are contained. The cost of the final device will depend considerably on the cost of the robotic arm and the software used, but it will certainly not exceed €1 million. For the electron-based IORT (IOERT), the medical device costs approximately €1.5 million.



Requested	2.5 Mln €
Investment target	Companies investing in research projects and with connections in medical fields

Lazarus by Omnidermal

Lazarus is a miniaturized and wearable device enabling real-time and remote rehabilitation therapy for patients, through continuous monitoring of muscle response and modulated stimulation of patients' muscles.

Field of activity and technology

Lazarus is an innovative medical device for telerehabilitation, and a potential tool for practitioners working in healthcare. It enables the movement of the healthy subject (e.g., a therapist) to be analyzed by an AI algorithm and then replicated on the patient through FES stimulation, making remote therapy implementation more accurate and effective, thus improving life-quality of patients while lowering costs.

Development stage

Omnidermal developed a first prototype and successfully tested it on a group of healthy patients.

Capital raised

200.000 €

Lazarus by Omnidermal

BUSINESS PROPOSAL

Lazarus is the first telerehabilitation solution integrating remote monitoring with a connected stimulation system in one miniaturized device. Lazarus can perform real remote rehabilitation without the need for direct contact between therapist and patient. It is also possible to use pre-recorded stimulation patterns previously collected by the therapist. This innovative system will be an important tool for healthcare professionals that will also guarantee continuity of care for all patients. In addition, Lazarus will make rehabilitation therapy more accessible and will allow for a better and faster patient recovery in hospitals, clinics, and nursing homes.

Omnidermal tested the first functioning prototype on healthy volunteers. The company is now looking for further investments to sustain the next steps of the project:

- Multicentric clinical trial on patients
- Development of final, commercial device
- CE certification (MDR 2017/745) & FDA approval
- Development of a new business market in telerehabilitation sector through new commercial partners



Requested	2.35 Mln € for innovation activities, business development and scale-up production
Investment target	Healthcare investors, companies active in the field of medical devices for rehabilitation

IppocraTech

IppocraTech has developed a technology that can simultaneously calculate the 5 vitals identified by the WHO to assess a person's health status. By simply touching the device, it will collect all the signals needed by IppocraTech's algorithms in the cloud to monitor heart rate and respiration, body temperature, blood saturation, one-lead ECG and blood pressure.

Field of activity and technology

Remote Patient Monitoring. This technology has been patented and received CE Class IIa certification. The technology has been approved through clinical studies in some important Italian hospitals and publications in international medical journals.

Development stage

Early Stage

Capital raised

5 Mln €



IppocraTech

BUSINESS PROPOSAL

IppocraTech aims to enter the US market by 2025, once FDA certification is obtained.
The goal is to raise €10 million by 31 December 2024 in order to enter the US market. IppocraTech currently has a unique technology in the world.
With this budget, all 5 vitals identified by WHO as the main indicators of an individual's state of health will be measured in a non-obtrusive way. In addition, the technology allowing lactate measurement non-invasively and in a non-obtrusive way will be developed.

Requested	10 Mln €
Investment target	Venture Capital

ALS monitoring by eSteps

eSteps is specialized in remote monitoring of multiple sclerosis and other neurodegenerative diseases to improve patient management. The company has developed a high-tech shoe insole connected via Bluetooth to an app that allows patients and their physicians to constantly monitor stability, gait and disease progression, enabling rapid treatment adjustments when indicated.

Field of activity and technology

Remote monitoring, health technology

Development stage

The company, with its headquarters in the United States, is finishing clinical validations to proceed to FDA clearance thereafter.

Capital raised

Is actively fundraising and has already joined two institutional VCs with $350.000

ALS monitoring by eSteps

BUSINESS PROPOSAL

eSteps is a fast-growing company that collaborates with major advisors who support the work in the field of multiple sclerosis and neurodegenerative diseases.
The company is seeking $1.5 million to clinically validate the service in movement disorder-related diseases and enter the market by the end of the year.



Requested	1.5 Mln €
Investment target	Pharma Company, Healthcare VC

Uell by Lingatech

UELL is a psycho-physical assessment digital platform.
It integrates 4 areas of science:
Genetics, Sports Sciences, Nutrition and Psychology.
The goal of UELL is to create the scientific basis for organizing training programs aimed at maintaining good health and wellbeing.

Field of activity and technology
From Fitness's customers to everyone

Development stage
Early adopters

Capital raised
150.000 €

Uell by Lingatech

BUSINESS PROPOSAL

1) Product's research and development
(Uell check, feedback loop, English language)
2) Uell analytics (Full Time Data Scientist)
3) Implementation of the B2C phase
4) Uell School (E-learning portal)
5) Improvement of new scientific tests

Why?

- Ethical and social motivations
- The Business Model is highly scalable and disruptive
- The target market is very large
- Huge future applications



Requested	1.5 Mln €
Investment target	Not specified

RunAware by Runbull

The environment affects the life and physiology of human beings, especially athletes who are exposed to environmental agents in a long-lasting manner during their outdoor activities. The use of Artificial Intelligence and Big Data tools has allowed us to develop the first model in the world that can measure the influence that bio-climatic conditions have on the body subjected to physical exertion.

Field of activity and technology

AI applied in Sport, Health, Nutrition and Wellness

Development stage

The company is currently engaged in the fundraising process necessary to complete the full functionality named «RunAware» and launch on the international market.

Capital raised

150.000 €



RunAware is an adaptive training solution that captures information from a range of wearable sensors with Edge-AI capabilities and cloud-based AI services for real-time analysis of human health and sports performance.



RunAware by Runbull

BUSINESS PROPOSAL

Despite the proliferation of wearable devices, dedicated apps and specialized websites, more than 200 million people worldwide practicing endurance sports (running, triathlon and cycling) train:

1. randomly;
2. with little chance of improving their performance;
3. with a high probability of accidents or health problems.

RunAware is the only solution available on the market that can measure the individual response of the organism both to physical exertion and to the environmental context in which it is carried out. RunAware offers both hyper-customized training programs aimed at improving performance and the best strategies to mitigate the health risks that competitive activity can entail.



Requested	750.000 €
Investment target	Healthcare VC, Sport VC

CLUST-ER HEALTH
SALUTE E BENESSERE

Clust-ER Health is an association made of large companies, SMEs, laboratories of the High Technology Network, research centers, health facilities and training institutions that share skills, ideas and resources to support the competitiveness of the Health Industries and Wellness of Emilia-Romagna.

EMILIA ROMAGNA GO HEALTHY

Regione Emilia-Romagna

INVEST IN ITALY

ITA ITALIAN TRADE AGENCY

CLUST-ER HEALTH SALUTE E BENESSERE

To get in touch with representatives of the companies, contact us via:

info@health.clust-er.it

http://health.clust-er.it

CLUST-ER HEALTH

SALUTE E BENESSERE

health.clust-er.it